Zimycan distribution
This article was originally published in The Tan Sheet
Executive Summary
Ft. Worth, Texas-based Healthpoint gets exclusive rights to market Barrier Therapeutics' antifungal ointment Zimycan to healthcare institutions in the U.S. and Canada under an agreement announced Sept. 13. Barrier cites Healthpoint's tissue management division as a good match for the product. The firm announced positive Phase III trial results for the candida-associated diaper rash cream in August after licensing the drug from Johnson & Johnson, where it had failed to gain approval as an OTC (1"The Tan Sheet" Aug. 16, 2004, p. 9). Barrier's NDA for Zimycan is currently pending at FDA...
You may also be interested in...
OTC Misfire Salvaged As Rx Prospect: Barrier Touts Antifungal Zimycan Trial
Barrier Therapeutics plans to parlay Johnson & Johnson's failed over-the-counter diaper cream Zimycan into the first prescription treatment for diaper rash complicated by Candida yeast infection
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.